Skip to content
#gene editing Review Open access

Metabolic-epigenetic regulation of the HBV cccDNA reservoir: pathways underpinning viral persistence

Oct 2026 · Frontiers in Microbiology · Vol 17 · 0 citations · 196 references
Medicine

TL;DR

Preclinical and clinical therapeutic strategies targeting the metabolic-epigenetic microenvironment, viral assembly, antigen secretion, and cccDNA modulation to achieve a functional cure for HBV infection are summarized.

Abstract

Chronic hepatitis B virus (HBV) infection remains a global public health burden, and functional cure represents the primary goal of clinical management. The nuclear covalently closed circular DNA (cccDNA) minichromosome stably maintained in infected hepatocytes constitutes the major barrier to HBV cure. Clinically, functional cure is defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with undetectable serum HBV DNA after finite treatment, a definition that does not require complete cccDNA elimination. At the molecular level, functional cure is thought to be associated with stable transcriptional silencing of cccDNA and integrated HBV DNA, a state biologically distinct from physical cccDNA depletion. Accumulating data demonstrate that the persistence and transcriptional homeostasis of the cccDNA reservoir are controlled by viral proteins and dynamically shaped by host metabolic signaling and epigenetic remodeling. Here, we first outline key steps of the HBV life cycle to establish the mechanistic context for cccDNA formation and replenishment, and then focus our synthesis on the integrated host metabolic-epigenetic network that governs cccDNA establishment, transcriptional activity, stability, and clearance. We dissect how central carbon metabolites, bile acid signaling, histone post-translational modifications, and immune cytokines converge to modulate cccDNA reservoir homeostasis, and critically evaluate the strength of evidence supporting their physiological relevance in the chronically infected human liver. We also discuss mechanisms of HBV immune evasion, including hepatitis B virus X protein (HBx)-driven epigenetic reprogramming and subviral particle-associated immune tolerance. We summarize preclinical and clinical therapeutic strategies targeting the metabolic-epigenetic microenvironment, viral assembly, antigen secretion, and cccDNA modulation to achieve a functional cure for HBV infection. Finally, we outline key unresolved challenges in the field, including the undefined in vivo cccDNA turnover kinetics, the poorly characterized physiological relevance of cell-to-cell transmission, the inherent limitations of gene-editing technologies, and the urgent need for specific non-invasive biomarkers reflecting intrahepatic cccDNA activity.

Read PDF

Similar papers

Review Open access Oct 2026

Host restriction factors in HBV-related liver disease and hepatocellular carcinoma: mechanisms of viral-host interplay and implications for therapy.

Chronic hepatitis B virus (HBV) infection is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC), imposing a substantial global health burden. The natural history of persistent HBV infection progresses from chronic inflammation to fibrosis, cirrhosis, and malignant transformation, driven in part by th...

Ze-Pei Li, Ye Qiu, Tom Luedde et al. · 0 citations
Open access Sep 2026

Development of an investigational epigenetic silencer therapy to transcriptionally inactivate viral DNA in chronic hepatitis B.

Approved chronic hepatitis B therapies rarely result in functional cure, as they fail to permanently silence all transcriptionally active hepatitis B virus (HBV) DNA. CRMA-1001 employs an optimized epigenetic silencer that represses viral transcription through targeted deposition of DNA methylation on episomal and inte...

Yesseinia I. Anglero-Rodriguez, Qiang Xiong, Martino Alfredo Cappelluti et al. · 2 citations
Open access Sep 2026

Intracellular Zn2+ levels regulate susceptibility to hepatitis B virus infection by modulating NTCP-mediated viral entry.

Hepatitis B virus (HBV) infection remains a significant global health challenge and is a leading cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma. Although nucleos(t)ide analogs and interferon-based therapies suppress viral replication, they do not eliminate the viral reservoir, highlig...

Yumi Itoh, Chiharu Morita, Jin-Zi Cui et al. · 0 citations
Open access Sep 2026

Resolution of viral R-loop by DHX9 promotes hepatitis B virus replication

ABSTRACT Hepatitis B virus (HBV) is a hepatotropic DNA virus with a compact 3.2 kb genome that replicates via reverse transcription. HBV covalently closed circular DNA (cccDNA) transcription shares molecular features with R-loop. DExH-box helicase 9 (DHX9) has been shown to be associated with R-loop accumulation, genom...

Yu-Bo Pi, Hui-Min Luo, Kai Wang et al. · 0 citations
Review Open access Oct 2026

Oligonucleotide and RNA-targeted therapeutics for chronic hepatitis B: Antigen reduction, delivery, and functional cure strategies

Chronic hepatitis B (CHB) remains difficult to cure because nucleos(t)ide analogs suppress hepatitis B virus (HBV) replication but do not eliminate covalently closed circular DNA (cccDNA) or integrated HBV DNA, which sustain viral RNA and hepatitis B surface antigen (HBsAg) production. RNA-targeted therapeutics, includ...

Xing-Chen Meng, Faisal Mahmood, Hui Li et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.